Discover more about the comorbidities of NASH / NAFLD through articles on NASH commentary content ▶ from a study obtained from expert doctors worldwide.
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and increased very low-density lipoprotein triglycerides (VLDL-TG)).
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing debate. MAFLD is based upon an individual having hepatic steatosis, as well as either type 2 diabetes mellitus, obesity (or being overweight) or if at a normal weight, two or more metabolic risk abnormalities.
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts and settings. FIB-4, a cost-effective marker, can be supplemented by complex multimarkers for NASH therapeutic trials. Embracing diagnostic imperfections is crucial for flexible biomarker algorithms.
NAFLD's prevalence in IBD patients raises concerns for cardiovascular risk. The study found doubled atherosclerotic cardiovascular disease risk in IBD patients with NAFLD. Transient elastography may predict cardiovascular risk in IBD patients. Targeted risk assessments are crucial for IBD patients with NAFLD.
Patients with T2D complications have a 4.5x greater risk of developing fibrosis, independent of HbA1c levels. FIB-4 index can help identify diabetic patients at highest risk, improving primary care screening.
Fatty liver disease (FLD) is found to be the strongest independent predictor of increased heart rate and reduced left ventricular volumes, and positively predicts cardiac remodelling
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease encompassing simple hepatic steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC).
Although it is known that non-alcoholic steatohepatitis (NASH) increases the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, no pharmacologic therapy has yet been approved to treat it.
This retrospective study by T. Mori et al. (Shanghai Jiao Tong University School of Medicine, China) aimed to investigate NAFLD frequency and identify factors associated with NAFLD presence at acute stroke admission.
The authors included stroke patients admitted from 2016 to 2019, within 24 h of onset...
This study aimed to investigate the association between serum uric acid level and NAFLD in 583 patients with type 2 diabetes (T2DM) hospitalised in the Department of Hepatology, Yantai Qishan Hospital (China). In this study, multivariate regression analyses demonstrated that after adjusting for confounding factors...